Aneurysmal Subarachnoid Hemorrhage
Conditions
Interventions
Experimental Group:Within 24 hours after randomization, patients will receive cilostazol 100 mg twice daily for 14 consecutive days, in addition to the standard aSAH treatment.
Control Group:Within 24 hours after randomization, patients will receive a placebo twice daily (bid) for 14 consecutive days, in addition to the standard aSAH treatment.
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-80 years. 2. Diagnosed with subarachnoid hemorrhage (SAH) by computed tomography (CT) scan, and the responsible aneurysm is clearly identified by computed tomography angiography (CTA) or digital subtraction angiography (DSA). 3. Received aneurysm coil embolization or craniotomy clipping within 72 hours of symptom onset. 4. Hunt-Hess grade II-IV. 5. No rebleeding or new intracranial hemorrhage is shown on head CT within 6 hours after surgery. 6. Understand and follow the procedures of clinical trial, participate voluntarily and sign the informed consent (the informed consent can be signed voluntarily by the person or guardian).
Exclusion criteria
Exclusion criteria: 1. Multiple aneurysms (>1aneurysms confirmed by CTA/DSA) . 2. Modified Rankin Scale (mRS) score >= 3 before onset. 3. Patients with contraindications to cilostazol use: Allergy to cilostazol;Severe heart failure(New York Heart Association (NYHA) Functional ;Classification Grade III or IV); Coagulation disorders or systemic bleeding (e.g., hemophilia, gastrointestinal bleeding, hemoptysis, etc.); Pregnant or lactating women. 4. Patients with severe organic diseases and an expected survival time of less than 90 days. 5. Severe liver insufficiency or renal insufficiency before randomization. 6. Aneurysm treatment requiring the use of other antiplatelet drugs after interventional therapy . 7. Currently receiving treatment with other investigational drugs or device trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Delayed cerebral ischemia (DCI); | — |
Secondary
| Measure | Time frame |
|---|---|
| Neurological function prognosis;Intracranial rebleeding events;Other severe bleeding events; | — |
Countries
China
Contacts
Public ContactLiping Liu
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed